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of	 cases	 and	 relevant	 publications	 has	 increased	 significantly	 (M.	





gators	with	a	 special	 interest	 in	 the	diagnosis	and	management	of	
MRONJ	 and	 a	 track	 record	 of	 relevant	 research	 and	 publications,	
who	considered	the	current	controversies	on	MRONJ	a	reason	for	
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consensus	on	these	topics	with	a	view	to	help	clinicians	making	in‐
formed	decisions	on	patient's	care	and	 inspire	future	 investigators	
to	design	better	 clinical	 studies.	 The	Group	 agreed	 to	 focus	upon	
three	highly	controversial	aspects	of	MRONJ:	(a)	definition	and	clas‐
sification,	(b)	risk	factors,	and	(c)	management/treatment	of	MRONJ.
2  | CONTROVERSIES ON DEFINITION AND 





been	 instrumental	 in	 the	process	of	establishing	an	understanding	











ing	 that	 a	 sub‐group	 of	 patients	 can	 in	 fact	 present	with	MRONJ	
disease	 characterized	 by	 the	 absence	 of	 exposed	 bone	 on	 visual	
inspection	(so‐called	non‐exposed	MRONJ,	 including	the	presence	






























task	 as	 an	 accurate	 case	 definition	 should	 ensure	 the	 exclusion	 of	
etiopathologically	different	disorders	presenting	with	similar	clinical	







controversies	 on	 management/treatment.	 Some	 authors	 have	 sug‐
gested	that	 that	up	to	one‐quarter	of	MRONJ	patients	can	present	
with	the	non‐exposed	variant	(Fedele	et	al.,	2015).	Although	this	pro‐





servation	 of	 potential	 MRONJ	 manifestation	 to	 fit	 the	 case	 defi‐
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to	develop	 following	a	 tooth	extraction	 (Otto	et	al.,	2018).	Dental	
extraction	was	reported	as	a	main	risk	factor	in	73%	of	the	cases	of	
ONJ	(Nicolatou‐Galitis	et	al.,	2011),	and	historically,	these	cases	have	



















main	 risk	 factor	 for	MRONJ	development.	Similarly,	 it	has	been	sug‐
gested	that	infection	around	the	implants	(peri‐implantitis)	represents	a	
notable	risk	factor	for	MRONJ	development	(Giovannacci	et	al.,	2016;	





have	been	triggered	by	dental	extraction	 in	 fact	 represent	cases	of	
non‐exposed	MRONJ	 that	 had	 already	 developed	 because	 of	 den‐
tal/periodontal	 infection	 before	 the	 actual	 extraction	 took	 place.	
Recent	 studies	have	 reported	 the	presence	of	histologically	proven	




















tive	high	dose,	use	 in	cancer	 setting,	and	 intravenous	administration	
(Abt,	2017;	Malden	&	Lopes,	2012;	Ruggiero	et	al.,	2014;	Vahtsevanos	
et	al.,	2009).	However,	 it	should	be	emphasized	that	 intravenous	ad‐
ministration	 of	 bisphosphonate	 per	 se	 should	 not	 be	 automatically	
considered	an	indicator	of	the	high	risk	of	MRONJ	development.	For	
example,	 some	osteoporosis	 patients	 receive	 yearly	 intravenous	bis‐
phosphonates;	however,	because	the	cumulative	dosage	remains	low,	
their	risk	of	developing	MRONJ	is	also	low.	Furthermore,	a	low	dose,	
usually	 quarterly	 or	 half‐yearly,	 of	 prophylactic	 intravenous	 bisphos‐
phonates	has	been	recently	 introduced	in	the	management	of	breast	








4  | CONTROVERSIES ON MANAGEMENT/
TRE ATMENT
Expert	 opinion‐based	 recommendations	 for	 the	 management	 of	
MRONJ	 are	 included	 in	 the	 AAOMS	 position	 papers	 (Advisory	
Task	Force	on	Bisphosphonate‐Related	Osteonecrosis	of	 the	 Jaws	
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AAOMS,	2007;	Ruggiero	et	al.,	2009,	2014).	The	Group	highlighted	




Accordingly,	 some	 authors	 advocated	 the	 adoption	 of	 treat‐
ments	 based	 also	 on	 the	 radiological	 aspects	 of	MRONJ	 disease	
(Campisi	et	al.,	2014)	 in	order	 to	pick	up	early	signs	of	disease	or	
base	 therapeutic	decisions	on	accurate	assessment	of	disease	ex‐












management	 of	 MRONJ	 patients.	 The	 AAOMS	 recommendations	
suggest	 generally	 non‐surgical	 treatment	 for	 stages	 1	 and	 2,	 and	
performing	surgical	debridement/resection	of	necrotic	bone	only	for	
stage	3	MRONJ	patients	(Advisory	Task	Force	on	Bisphosphonate‐










A	 recent	 study	 also	 suggests	 that	 non‐surgical	 therapy	might	
lead	 to	 progression	 of	 MRONJ	 disease.	 Ristow	 et	 al.	 (2019)	 de‐
scribed	 a	 longitudinal	 study	 of	 92	 patients	with	 stage	 1	MRONJ	
who	 were	 initially	 treated	 by	 using	 a	 standardized	 conservative	
(non‐surgical)	 protocol	 consisting	 of	 antimicrobial	 mouth	 rinsing	
and	 gel	 application	 (with	 chlorhexidine).	 The	 authors	 reported	
that	only	8	patients	(8.7%)	showed	complete	mucosal	healing	and	






well‐designed	 comparative	 trials	 are	 required,	 there	 is	 increasing	
evidence	 suggesting	 that	 surgical	 removal	 of	 the	 necrotic	 bone	
might	 provide	 long‐lasting	 benefits	 to	MRONJ	 patients	 in	 terms	
of	resolving	symptoms,	obtaining	mucosal	healing,	and	preventing	









5.1 | Key statements and recommendations relevant 






•	 Stage	 0	 of	 the	 AAOMS	 classification	 is	 a	 diagnostic	 challenge,	
as	 there	 are	 overlaps	 with	 dental	 and	 non‐dental	 diseases.	
Stage	 0	 may	 ultimately	 need	 confirmation	 by	 imaging	 and/or	
histopathology.
•	 Cases	of	non‐exposed	MRONJ	without	fistula	should	be	included	
in	 the	 definition,	 possibly	 in	 terms	 of	 suspected	 or	 probable	
MRONJ	after	ruling	out	other	dental	and	non‐dental	disease.	The	
only	 ultimate	 proof	 of	 non‐exposed	MRONJ	 might	 be	 the	 his‐
topathologic	 confirmation	of	necrotic	bone.	Decision	on	biopsy	
should	be	taken	on	an	individual	basis.







•	 Present	 classification/staging	 does	 not	 adequately	 capture	 the	
extension	 and	 severity	 of	MRONJ	 lesions.	 This	may	 potentially	
affect	treatment	and	prognosis.
5.2 | Key statements and recommendations 
relevant to risk factors for MRONJ
•	 Tooth	 extraction	 does	 not	 automatically	 translate	 into	 an	 in‐
creased	risk	of	developing	MRONJ,	as	certain	surgical	procedures	
notably	reduce	the	risk.
•	 The	 reported	 high	 risk	 of	 developing	 MRONJ	 after	 tooth	 ex‐
traction	might	 be	 related	 to	 an	 underlying	 pre‐existing	 dental/
periodontal	infection	rather	than	to	the	surgery	per	se.
•	 The	 risk	 of	 developing	 MRONJ	 is	 not	 related	 to	 the	 way	 of	
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administration	as	single	factor;	an	accurate	risk	assessment	should	
include	an	evaluation	of	 the	cumulative	dosage	and	duration	of	
anti‐resorptive	 treatment.	 Typically,	 high‐dose	 anti‐resorptive	
therapy	 given	 to	 cancer	 patients	with	metastases	 is	 associated	
with	higher	risk	of	MRONJ	development	as	compared	to	low‐dose	
therapy	given	to	osteoporosis	patients.
5.3 | Key statements and recommendations 
relevant to management/treatment of MRONJ
•	 Because	 there	 is	 no	 accurate	 staging	 system	 reflecting	 the	 ex‐
tension	of	MRONJ	bone	disease,	 it	 is	problematic,	 and	possibly	
misleading,	to	inform	treatment	recommendations	on	the	basis	of	
currently	available	staging	systems.
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